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We reviewed the clinical results of a dendritic cell-based phase II clinical vaccine trial in stage IV melanoma and analyzed a
patient subgroup treated with standard therapies after stopping vaccination. From 2003 to 2009, 24 metastatic melanoma patients
were treated with mature dendritic cells pulsed with autologous tumor lysate and keyhole limpet hemocyanin and low-dose
interleukin-2. Overall response (OR) to vaccination was 37.5% with a clinical beneﬁt of 54.1%. All 14 responders showed delayed
type hypersensitivity positivity. Median overall survival (OS) was 15 months (95% CI, 8–33). Eleven patients underwent other
treatments (3 surgery, 2 biotherapy, 2 radiotherapy, 2 chemotherapy, and 4 biochemotherapy) after stopping vaccination. Of these,
2 patients had a complete response and 5 a partial response, with an OR of 63.6%. Median OS was 34 months (range 16–61). Our
results suggest that therapeutic DC vaccination could favor clinical response in patients after more than one line of therapy.
1.Introduction
Melanoma accounts for 1%–3% of all malignant tumors and
its incidence is increasing in western countries by 6%–7%
each year [1–3]. The disease is curable in more than 50% of
caseswithsurgicalresection,withanexpected5-yearsurvival
of 80%–100% [2]. However, prognosis is poor for patients
with advanced disease, with a 5-year life expectancy of <10%
and a median survival of 6–8.5 months [4]. Chemotherapy
for advanced melanoma continues to be highly unsatis-
factory [5, 6]. Dacarbazine (DTIC) is still considered the
gold standard of therapy, despite the fact that it has shown
“placebo” results in recent phase III trials, obtaining <10%
overall response (OR) rates, with an overall survival (OS)
of around 6 months [7–9]. Diﬀerent monochemotherapies
and polychemotherapeutic associations, with or without the
addition of biological response modiﬁers, have not proven to
be more eﬀe c t i v et h a nD T I C[ 10, 11]. There are no standard
second- or third-line therapies.
The relation between the immune system and the tumor
is undoubtedly a complex one. The key ability to distinguish
between self and non-self is essential for an adequate
response to external pathogens and growing tumor cells.
[12] Basic research has identiﬁed a number of mechanisms
underlying spontaneous antitumor immunity and enabled
Dunn to formulate the cancer immunoediting hypothesis,2 Clinical and Developmental Immunology
whichdivides the tumor immune response into three phases:
elimination, equilibrium,a n descape [13, 14].
Both innate and adaptive immunity are involved in
the antitumor immune response [15, 16]. In particular,
dendritic cells (DCs) play a crucial role in the interplay
between innate and adaptive response towards cancer [17].
As members of the innate immune system, their main
function is to present antigens to regulate the activation of
the adaptive response. DCs can therefore provide signals of
both immunostimulation and tolerance to antigen-speciﬁc
T lymphocytes, thus determining the T response (Th1/Th2)
whichdependsontheactivationstatusoftheDCsatthetime
of the interaction [18, 19]. There is a convincing rationale
for the use of DC-based vaccine. In their review of clinical
vaccination trials, Rosenberg et al. observed the highest
response rate among studies using dendritic cells (7.1%)
[20]. Engell-Noerregaard et al. reviewed 38 publications
on clinical trials (from 1996 to 2007) using DC-based
vaccination in advanced melanoma. The authors reported
an objective response rate of 9% with a clinical beneﬁt of
30% (CR+PR+SD) and 21% stable disease. Although a trend
was observed between immunological response and overall
survival, no deﬁnitive conclusions were drawn [21].
A combination of immunotherapy with standard treat-
ments (chemotherapy, radiotherapy, and surgery) for cancer
is an emerging challenge and an emerging paradigm, in con-
trast to the concept that deﬁnes most standard treatments as
immunosuppressive. Examination of combined treatments
has yielded unexpected results. Antonia et al. reported a
very strong objective response to second-line chemotherapy
in nonsmall cell lung cancer patients pretreated with vac-
cination consisting of dendritic cell (DC) transduced with
the full-length wild-type p53. This vaccination was started
8 weeks after completion of ﬁrst-line chemotherapy [22].
A similar observation was made in patients with follicular
B-cell lymphoma vaccinated with an anti-idiotype vaccine
while in remission. At disease recurrence, patients were
treated with second-line chemotherapy (CHOP schedule)
obtaining a much higher partial or complete remission than
those expected for this disease [23]. Similarly, Gribben et al.
reported unexpected high response rates to salvage therapies
after vaccination with universal tumor antigen CYP1B1 in
solid tumors in a phase I trial. Five vaccinated patients
who developed immunity to the vaccine had a marked
o b j e c t i v er e s p o n s et os u b s e q u e n tt h e r a p i e s[ 24]. In a review
of 3 prostate cancer vaccine trials, researchers underlined
that vaccinated patients responded better to subsequent
chemotherapy than those who had not been vaccinated
[25]. The mechanisms responsible for such results remain
unknown, although some data have been published on the
eﬀect of gemcitabine on myeloid-derived suppressor cells
(MDSC) and on the activity of paclitaxel, which binds toll-
like receptors (TLRs) to dendritic cells and induces the
production of patterns typical of T-helper type I [26].
On the basis of the above, we reviewed and updated
the clinical results of a dendritic cell-based clinical vaccine
trial in stage IV melanoma patients [27], focusing on a
subgroup of 11 patients who underwent other therapies after
vaccination.
2. Patients andMethods
2.1. Patient Population. From June 2003 to December 2007,
24 patients with metastatic melanoma were treated with
mature-DCs(mDCs)(10M/vaccine)pulsedwithautologous
tumor lysate (ATL) and keyhole limpet hemocyanin (KLH).
All but 3 of the patients had been heavily pretreated before
vaccination. Patients were vaccinated intradermally with
mDCs at the base of the thigh about 10cm from the groin.
Interleukin-2 (IL-2) was administered subcutaneously at a
dose of 3 MIU/die on days 3, 4, 5, 6, and 7. The procedure
was repeated every 2 weeks for four cycles and monthly
thereafter until the lysate was ﬁnished or evident progression
occurred (symptomatic progression or worsening of clinical
conditions with a PS > 2 and absence of signs of immunos-
timulation). Disease evaluation and immunomonitoring in
vivo with delayed-type hypersensitivity (DTH) for both ATL
and KLH were performed before the ﬁrst vaccination and
everyfourcyclesthereafter.Theprotocolwasapprovedbythe
Local Ethics Committee of Forl` ıH e a l t ha n dS o c i a lS e r v i c e s
(Azienda USL di Forl` ı) in 1999.
Prevaccination treatment was as follows: radiother-
apy and radical surgery for brain metastases (1 patient),
leg perfusion (1), 3 lines of chemotherapy (1), ﬁrst-line
chemotherapy and biochemotherapy after lung metastasis
resection (1), high-dose interferon (IFN) for 9 months and
bone radiotherapy (1), chemotherapy after low-dose IFN (1)
and biochemotherapy (1), or no therapy (2).
Eleven patients underwent other treatments after stop-
ping vaccination due to disease progression (8 patients)
or because the ATL was ﬁnished (3, of whom 2 had
PR and 1 SD). Of these, 3 underwent high-dose IFN, 2
low-dose IFN, and 6 no treatment. Median disease-free
survival (DFS) (from exeresis of primary melanoma to ﬁrst
relapse) was 36 months (range 6–108). Two patients had
high LDH levels before vaccination which further increased
after treatment. Sites of metastasis after vaccination in
the subgroup were lymph nodes (6 patients), soft tissue
(7), kidney (2), lung (3), and liver (1). Subsequent treat-
ments were as follows: surgical palliative intervention (3
patients, each undergoing >1 nonradical surgical interven-
tion), biotherapy with anti-CTLA-4 monoclonal antibody
in a clinical trial (2 patients, one of whom also received
hepatic locoregional fotemustine and chemotherapy with
dacarbazine [DTIC] and the other, Gamma Knife radio-
surgery for brain metastases and fotemustine), chemother-
apy (cisplatin [CDDP] plus DTIC-based polychemotherapy)
(2), low-dose biochemotherapy (CDDP+DTIC+IL-2) (2),
chemotherapy with CDDP+DTIC and high-dose IL-2 (1),
and biochemotherapy (CDDP+DTIC+ low-dose IL-2) plus
Gamma Knife radiosurgery (1) (Table 1).
2.2. Inclusion Criteria for Vaccine Therapy. Age < 70 years,
histologically conﬁrmed diagnosis of melanoma, measur-
able disease (excluding the presence of brain metastases),
previous removal of one or more metastatic lesion from
which a suﬃcient quantity of ATL had been obtained for at
least 6 vaccinations, Performance Status (PS) ≤ 2 (according
to ECOG criteria), life expectancy > 4 months. PatientsClinical and Developmental Immunology 3
Table 1: Patients who underwent subsequent therapies after vaccine.
Patient Adjuvant
therapy
DFS
(months)
Prior
treatment
(Prevaccine)
Prevaccine
LDH
Postvaccine
LDH
Postvaccine
treatment
Postvaccine
treatment
LDH
Best
Response
Sites of
evaluable
metastases
2 P.M. No 12 BioCT 366 627§ CT 411 SD Lung,lymph
nodes
4 G.D. HD-IFN 37 no 332 406 CT 310 PR Lymph
nodes HD-IL-2
6T . A . N o 6
CT and
RT+surgery
for brain
metastases
334 281 BioCT na PR Soft tissue
8C . P . N o 4 8 Locoregional
CT (arm) 256 245 BioCT na PD Soft tissue
11 M.J. LD-IFN 108 CT 193 265
Surgery,
Gamma Knife
(brain)
384 CR+
∗ Lung,
kidney, skin,
lymphnodes
Lung surgery,
BioCT
15 B.F No 57
Arm
perfusion,
BioCT, surgery
603§ 686§ Surgery 433 PR+
∗
Lymph
nodes, soft
tissue
17 B.I No 9 BioCT 236 234 Surgery 254 PR+
∗
Lung,
adrenal
gland
18 S.L HD-INF 36 CT (3 diﬀerent
lines) 374 311
CT, RT
(brain),
anti-CTLA-4
antibodies
708§ PD
Lymph
nodes, soft
tissue
22 M.C. LD-IFN 18 No 591§ 988§
Hepatic
loco-reg CT,
DTIC
anti-CTLA4ab
493 PR Liver, soft
tissue
23. R.G HD-IFN 48 Bone RT 299 313 BioCT,Gamma
Knife (brain) na CR+ Lung, bone
24. B.R No 24 CT, LD-IFN 236 234 BioCT na PD
Lung, soft
tissue,lymph
nodes
Adj: adjuvant; T: treatment; V: vaccine; HD-IFN: high-dose interferon; BioCT: biochemotherapy; CT: chemotherapy; RT: radiotherapy; LD: low dose; anti-
CTLA4ab, anti-CTLA4 monoclonal antibody; §,e l e v a t e d ; ∗, responses obtained alternating palliative surgery with vaccine.
who were in good clinical condition (ECOG ≤ 2) but had
stopped vaccination due to disease progression or because
the ATL was ﬁnished were treated with subsequent standard
chemotherapy.
2.3. Autologous Tumor Lysate (ATL) Preparation. Surgically
removed tumor samples were mechanically dispersed to cre-
ateasingle-cellsuspension.Thelargestpieceswereincubated
at 37
◦C in enzyme mix (collagenase 0.1%, hyaluronidase
0.01%, DNAse 0.1%, Sigma, Milan, Italy) in RPMI 1640,
(PAA Laboratories GmbH, Pasching, Austria) for 3 hours. At
the end of incubation the pellets were washed 3 times with
phosphate buﬀered saline (PBS) and incubated for at least 20
minutesinsteriledistilledwater.Lysiswasmonitoredbylight
microscope. Larger particles were removed by centrifugation
(10min at 600g) and the supernatant was passed through
a0 . 2 - μm ﬁlter. Protein contents were determined and
aliquots were stored at −80
◦C until use, after veriﬁcation of
sterility.
2.4. DC Generation. DCs were prepared from peripheral
blood monocytes (PBMCS) obtained by leukapheresis
without previous mobilization. Five to nine liters of blood
were processed in each collection. PBMCs were puriﬁed on
Ficoll-Paque. An aliquot of PBMC was utilized immediately
f o rD Cg e n e r a t i o na n dt h er e s tw a sf r o z e ni nb a g sf o ru s ea ta
later date (4–5bags/each collection). PBMC were incubated
in tissue culture ﬂasks with CellGro DC medium (Cell
Genix, Freiburg, Germany) at 10 × 106cells/mL for 2 hours.
The nonadherent cells were discarded and the adherent
cells were incubated in CellGro DC medium containing
1000IU/mL rhIL-4 and 1000IU/mL rhGM-CSF (Cell Genix,
Freiburg, Germany) for 7 days to generate a DC-enriched
cell population. On day 6, 90% of the DC culture was
pulsed with ATL/ATH (100mg/mL), while the remaining
10% was pulsed with KLH (50mg/mL). Both cultures were
then incubated overnight. On day 7, the cells were deﬁned
as immature DCs (iDCs). After eliminating the previous
culture medium, pulsed iDCs were cultured for a further 24 Clinical and Developmental Immunology
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Figure 1: CT scan of patient n. 25 (BI) before and at the end of vaccination cycles. The red circle indicates the PR observed to vaccine.
The patient underwent palliative surgery following progression in adrenal gland and abdominal lymph node metastases after stopping
vaccination and has ongoing PR in the lung.
days with a cocktail of cytokines (TNFα,I L - 1 β,I L - 6 ,C e l l
Genix, Freiburg, Germany; PGE2, Pﬁzer, Italy). On day 9
they were deﬁned as mature DCs (mDC). iDCs or mDcs
were removed, washed, and suspended in sterile saline for
therapeutic infusion into the patient.
2.5. Delayed Type Hypersensitivity. ATL (10 μg) and KLH
(5μg )w e r ee a c hs u s p e n d e di n5 0 0 μL of PBS and injected
intradermally into the forearm of the patient. PBS alone
was used as negative control. Patients received intradermal
injections of ATL, KLH, and physiological solution as
negative control at separate sites on the forearm. Eight and
twenty-four hours later, DTH was assessed by determining
the area of erythema and induration using two-dimensional
measurements. The DTH response was considered to be
positive if the area of erythema was >10mm.
2.6. Statistical Analysis. Evaluation of response to vaccina-
tion was carried out according to modiﬁed RECIST criteria,
and mixed responses were thus evaluated (decrease in or
disappearance of lesions with appearance of new lesions or
with modest progression in others). In the event of modest
progression, good PS (<2) and positive DTH, vaccination
was carried out [28]. Response to postvaccine treatments
(11 patients) was carefully evaluated by RECIST criteria, and
survival time was calculated as the time between the date of
the ﬁrst vaccination and the date of death from any cause
[28] or last followup (June 2009). Overall survival curves
were calculated by the Kaplan-Meier method and compared
using the Gehan-Wilcoxon test, which tends to weigh the
early diﬀerences more heavily than other tests belonging to
the two-sample rank test family [29].
3. Results
3.1. Patient Characteristics. Twenty-four patients (13 males
and 11 females) with a median age of 50 (range 34–75
years) entered the study. Sites of evaluable metastases were
viscera (20 patients), bone (1), soft tissue (14), and lymph
nodes (13). Prevaccine treatments were biochemotherapy
(12patients),chemotherapy(7),biotherapy(1)radiotherapy
(3), or no therapy (3) (Table 2).
3.2. Update of Clinical Vaccine Results. Of the 24 patients
treated with vaccine, 2 showed complete response (CR), 2
mixed response (MR), 5 partial response (PR) (Figure 1),
and 5 stable disease (SD). The overall response (OR) rate
was 37.5% with a clinical beneﬁt of 54.1%. All 14 responders
had DTH-positivity to KLH, 10 of whom also to ATL
(Table 3). Median overall survival (OS) was 15 monthsClinical and Developmental Immunology 5
Table 2: Patient characteristics.
Median age 50 years (range 34–75) Patients (n = 24) n (%)
Sex
Male 13 (54.2)
Female 11 (45.8)
Sites of evaluable disease
Viscera 20
Bone 1
Soft tissue 14
Lymph nodes 13
Previous treatments
BioT 1
BioCT 12
CT 7
RT 3
No treatment 3
(C.I 95%: 8–33). In a previous study [27], we also observed
a statistically signiﬁcant diﬀerence in OS between DTH-
positive and DTH-negative patients, which seems to have
been maintained, with a median OS of 21 months for DTH+
patients and 7 months for DTH−patients (Gehan-Wilcoxon
test; P = .046) (Figure 2). Figure 3 shows the subdivision
of clinical responses on the basis of DTH positivity to ATL
only. Patient 19 obtained a CR (Figure 4)o f1 5m o n t h s
(up to June 2009) with alternating non radical surgery
and vaccination, as did patients 23 and 25, whose PR is
ongoing. These 3 patients are included in the subgroup
analysis because surgery was either considered palliative
therapy or used to obtain more ATL vaccination or symptom
control.
3.3. Subgroup (Postvaccine Treatments) Results. The overall
response rate to subsequent therapies was 63.6% with
2 CR (1 patient treated with surgery alternating with
vaccine and radiosurgery (Gamma Knife) for a small
brain metastasis, 1 treated with biochemotherapy plus
radiosurgery (Gamma Knife) for a single brain metastasis)
and 5 PR (2 patients treated with surgery, 1 patient receiving
hepatic locoregional fotemustine+DTIC+anti-CTLA-4
antibody, 1 submitted to DTIC+CDDP and high-dose IL-2,
and 1 treated with CDDP+DTIC+ low-dose IL-2), with a
median OS of 34 months (median range 16–61). Five of
these patients had received one or more treatments before
vaccination and experienced an objective response. Of the
11 subgroup patients, 3 had high LDH serum levels after
vaccination which normalized during subsequent treatments
administered for progressive disease (Table 1). All but one of
the patients also had DTH-positivity to at least the KLH test,
while6werealsopositive toATLaftervaccination(Figure 5).
3.4. Toxicity. Apart from swelling, redness, and pruritus
around the site of inoculation, no noteworthy toxicities or
side eﬀects were observed following vaccination. A low fever
with mild ﬂu-like symptoms (grade 1-2) was present during
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Figure 2: Update of OS curves in 24 vaccinated patients according
to DTH (P = .046).
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Figure 3: Subdivision of clinical response to DC vaccination on the
basis of DTH positivity to lysate (ATL) for the 24 patients treated.
administration of IL-2 from days 3 to 7. No autoimmune
phenomena were observed apart from the onset of vitiligo
in 3 patients, hypothyroidism in 2 and the ﬂaring up
of a preexisting vitiligo in one patient (all responders).
Toxicity linked to subsequent treatments was coherent with
that expected from the diﬀerent schedules used and no
unexpected adverse events were observed.
4. Discussion
Systemic therapy for metastatic melanoma remains disap-
pointing and median survival is not improved signiﬁcantly
by currently available chemotherapy regimens [29]. Clinical
response rates to most single agents are lower than 15% [30–
34], whereas drug combinations have produced response6 Clinical and Developmental Immunology
MJ
PET 02/09/2005
MJ
PET 27/02/2007
MJ
PET 30/03/2009
Figure 4: PET/CT scans of patient n 19 (MJ) performed in September 2005 (positive PET scan in several metastatic sites), February 2007,
and March 2009 (negative PET scan for metasteses). During this period the patient underwent palliative surgery for symptomatic disease
(e.g., hematuria due to renal metasteses) or to collect ATL for vaccination that started in February 2005 and terminated in June 2008 because
the ATL was ﬁnished. Radiosurgery (Gamma Knife) was carried out on a small brain lesion in January 2008. The patient is still in CR
(negative PET scan May 2010).
Table 3: Update (June 2009) of results on 24 patients treated with mDC vaccine.
Patient ID n vaccinations DTH Best response after 4 or more vaccinations Vitiligo Clinical
response
Response
duration OS (Months)
ATL KLH
(1) P.M 7 −− PR 3 14
(2) P.M 15 ++ ++++ MR 6 22
(3) R.L. 10 − ++ SD 9 14
(4) G.D. 16 ++ + ++ + CR 8 34
(5) R.G. 4 − +++ PD — 8
(6) T.A. 13 − ++ MR 12 41
(7) B.A. 4 −− PD — 7
(8) C.P. 6 − ++ PD — 20
(9) O.M. 4 −− PD — 5
(10) LB. 4 −− PD — 3
(11) M.J. 8+8+8+4 + + ++ + CR 15+
∗ 52+
(12) O.G. 5 −− PD — 3
(13) M.R. 4 + ++ PD — 6
(14) DiI.G 10 + + CR 36+ 39+
(15) B.F 21 ++ ++ PR 20+
∗ 40+
(16) I.I 6 −− PD — 7
(17) B.I 4 ++ −/+ + PR 21+
∗ 31+
(18) S.L 9 − +S D 7 2 2
(19) N.F. 6 ++ + PR 5 8
(20) B.R 12 + ++ + ++ SD 8 10
(21) S.M 11 −− PD — 12
(22) M.C 6 − + PD — 61+
(23) R.G 5 −− PD — 60+
(24) B.R 13 + + ++ SD 11 16
PR: partial response; MR: mixed response; SD: stable disease; CR: complete response; PD: progressive disease; OS: overall survival; DTH: delayed-type
hypersensitivity test; ∗responses obtained with palliative surgery + vaccine alternating; Grey area, 11 patients given postvaccine therapy.Clinical and Developmental Immunology 7
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Figure 5: Subdivision of DTH positivity (+) and negativity (−)
to lysate (DTH positivity to KLH is contained in the negative
group) grouped on the basis of single response and clinical beneﬁt
(CR+PR+SD).
rates of up to 40% [8, 10, 35]. Although a combination of
cytotoxic chemotherapy with biological response modiﬁers
such as IL-2 and IFN has resulted in overall response rates
of 40%–60% with about 10%–20% CR, biochemotherapy
cannotbeoﬀeredtoasubstantialproportion ofpatientswith
metastaticmelanomabecauseofitshightoxicity[11,36–40].
Furthermore, recent phase III trials have not demonstrated a
clear survival beneﬁt from biochemotherapy compared with
that obtained with conventional chemotherapy in patients
with metastatic melanoma [30, 41–43]. As demonstrated in
most of the phase III studies carried out on combination
regimens, the incidence of toxicity increases as more drugs
are combined and there is no improvement in median
survival. New drug regimens are therefore needed with less
morbidity than biochemotherapy but more potent antitu-
mor activity than current standard chemotherapies. In fact,
understanding how melanoma overcomes host immunity
could be the key to developing strategies targeting compo-
nents of the antitumor immune response, for example, anti-
CTLA-4 agents, which has produced encouraging results.
Durable objective response rates have been in the range of
4.6%–15% for patients with metastatic melanoma, with a
further increment in long-term SD or progression followed
by response [44–46].
Speciﬁc tumor vaccines attempt to reverse tumor-
induced immune suppression and it is thought that they may
prolong survival in immune-responsive patients. Vaccines
would seem to trigger immunologic memory and thus
subsequent treatments that are capable of upregulating
tumor-associated antigen expression or of enhancing cross-
presentation in a toll-like receptor 4 dependent manner
following chemotherapy- or radiotherapy-induced tumor
cell death appear to more successful [47]. A progressive
surgical reduction of the tumor mass also seems to intensify
the eﬀect of the vaccine.
We observed an OR of 63.6%, which, albeit infrequent
in metastatic melanoma after failure of at least one line of
therapy, is nevertheless in line with other data published
on the treatment of other solid tumors. In our case series,
although the 11 patients subjected to postvaccine therapy
all had a fairly long initial DFS (median of 36 months)
and 5 had also responded to ﬁrst-line therapy, the response
percentage observed after 3-4 lines of therapy was unusually
high. It must be underlined that all but one of the 11 patients
treated after vaccination had positive DTH to KLH (6/11
also positive to ATL), which seems to support the hypothesis
thatimmunoreactivepatientsmaybeneﬁtfrombeingtreated
even after the failure of vaccine therapy. This highlights the
potential usefulness of using vaccine treatment sooner rather
than later with the aim of promoting further therapeutic
response. In fact, the combination of vaccine with surgery
could be eﬀectiveinreducingtheneoplasticmass,facilitating
the eﬀect of immunotherapy. Radiotherapy plus vaccination
is thought to induce an abscopal eﬀect [48, 49], while
chemotherapy, in addition to reducing tumor burden, may
induce lymphocytopenia in immunosuppressive cells such
as T-regulator lymphocytes [50] .I tm a ye v e nb ep o s s i b l et o
improve the eﬀect of DC vaccine by combining it with drugs
that induce a stronger immunological response (Toll-like
receptors) or with agents that inhibit immunosuppression
such as antiCTLA-4 antibody. Finally, it would perhaps be
useful now to search for predictive factors of immunosup-
pression, for example, TEM8 expression in dendritic cells.
This marker, evaluated at baseline in 4 of the subgroup
patients, was low in 3 responders to subsequent therapies
and high in one progressive patient, which would seem
to conﬁrm previously reported ﬁndings by Venanzi et al.
[51].
Inconclusion,itisclearthatthesmallnumberofpatients
and the retrospective setting does not permit any deﬁnitive
conclusions to be drawn. However, we do feel that our
data, together with other ﬁndings published in the literature,
could form the basis to design new, eﬀective combined
treatment strategies. As suggested by other authors [52], it
might be useful, for example, to bring forward the time of
vaccination with respect to other treatments or to consider
the potential of alternating immunotherapy (vaccine alone
or vaccine+adjuvant, such as anti-CTLA-4 antibodies) with
chemo/radiotherapy or surgery.
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